Gastric Cancer

Acid suppressant-associated gNETs have an indolent course, are often multiple, and are frequently associated with very prolonged PPI/H2RA use. Unconventional morphologies like those described in type 1 gNETs may be observed.

The correspondence rate between primary PDAC and the matched metastatic sites was: 70.0% for PDAC/LNM, 93.3% for PDAC/PM, and 100.0% for PDAC/LIVM. This study shows a high rate of correspondence of CLDN18-positivity between primary PDAC and different metastatic sites, providing a strong rationale for further exploring and testing anti-CLDN18.2 therapeutic strategies in this lethal malignancy.

No first-line regimen significantly improved OS or PFS in HER2-positive advanced gastric cancer. However, HLX22-based and immune-combination strategies show potential clinical value-particularly in enhancing ORR-and merit further investigation.

This study found no significant association between H. pylori infection and types of tumor markers (CEA and CA19-9) among Yemeni gastric cancer patients. However, the significant association between H. pylori infection and site of gastric cancer in cardia and fundus regions needs further investigations to reveal the associated mechanisms.

P=N/A, N=2000, Recruiting, Flinders University of South Australia | Not yet recruiting --> Recruiting

Integrating these outputs with clinical variables, the MPMR-IMCP risk model significantly outperformed clinical-only models (ΔAUC = 0.050), enabling both phenotype analysis and GIM risk stratification without specialized staining. Validated in longitudinal cohorts from Chinese GC high-incidence regions, this framework offers an efficient solution for monitoring GIM malignant transformation.

Our findings thus underscore the pivotal role of the USP29 and SMURF1 in regulating GC chemoresistance via FSP1-mediated ferroptosis suppression. FSP1 inhibition may represent a promising therapeutic avenue to overcome chemoresistance in GC.

No recurrence was observed during the 12-month follow-up. This case highlights the diagnostic pitfalls of this entity, and underscores the importance of accurate pathological recognition to guide clinical management.

BRU inhibites GC progression by targeting P4HA2, disrupting glycolysis-histone lactylation signaling, and downregulating TTK. This metabolic-epigenetic mechanism positions BRU as a promising natural therapeutic for GC.

P1, N=56, Active, not recruiting, Legend Biotech USA Inc | Recruiting --> Active, not recruiting

In esophageal tumors, adjuvant nivolumab is used. Among HER2-positive patients, adding pembrolizumab to trastuzumab and chemotherapy - in PDL1 CPS ≥1 cases - has become a new standard. A special mention must be made of MSI-H tumors, in which immunotherapy is highly effective, and adjuvant chemotherapy is not recommended according to current guidelines.

In summary, base editor screen provides a versatile approach for exploring the role of phosphorylation sites in cancer chemotherapy. The METTL3-eIF3H interaction may serve as a potential therapeutic target.